Literature DB >> 1356531

Development of ulcerative colitis under the immunosuppressive effect of cyclosporine.

J Passfall1, A Distler, E O Riecken, M Zeitz.   

Abstract

In recent studies, cyclosporine has been used for the treatment of both ulcerative colitis and Crohn's disease. The results of these studies were variable. We report on a patient who was treated for 6 years with cyclosporine after kidney transplantation. He developed chronic distal colitis with all the features of ulcerative colitis. An infectious etiology of the colitis was carefully excluded. High-dose treatment with methylprednisolone was required to induce remission. This report shows that immunosuppressive therapy with cyclosporine did not prevent the development of ulcerative colitis in this patient.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1356531      PMCID: PMC7087535          DOI: 10.1007/bf00184805

Source DB:  PubMed          Journal:  Clin Investig        ISSN: 0941-0198


  13 in total

1.  Cyclosporine in Crohn's disease--low doses won't do it.

Authors:  C O Elson
Journal:  Gastroenterology       Date:  1990-05       Impact factor: 22.682

2.  Unsatisfactory effect of cyclosporin A treatment in Crohn's disease: a report of five cases.

Authors:  R Löfberg; B Angelin; K Einarsson; N Gabrielsson; L Ost
Journal:  J Intern Med       Date:  1989-09       Impact factor: 8.989

3.  Oral administration of cyclosporin does not prevent expansion of antigen-specific, gut-associated, and spleen lymphocyte populations during Chlamydia trachomatis proctitis in nonhuman primates.

Authors:  M Zeitz; T C Quinn; A S Graeff; R Schwarting; S P James
Journal:  Dig Dis Sci       Date:  1989-04       Impact factor: 3.199

4.  Cyclosporin in ulcerative colitis.

Authors:  S Gupta; A Keshavarzian; H J Hodgson
Journal:  Lancet       Date:  1984-12-01       Impact factor: 79.321

5.  Remission of Crohn's disease after human immunodeficiency virus infection.

Authors:  S P James
Journal:  Gastroenterology       Date:  1988-12       Impact factor: 22.682

Review 6.  The immunologic basis of inflammatory bowel disease.

Authors:  W Strober; S P James
Journal:  J Clin Immunol       Date:  1986-11       Impact factor: 8.317

7.  Treatment of Crohn's disease in relapse with cyclosporin A.

Authors:  N R Parrott; R M Taylor; C W Venables; C O Record
Journal:  Br J Surg       Date:  1988-12       Impact factor: 6.939

8.  [Cyclosporin A in acute Crohn disease: initial findings].

Authors:  U A Marbet; K Gyr; G A Stalder
Journal:  Schweiz Med Wochenschr       Date:  1986-07-19

9.  Cyclosporin A treatment in inflammatory bowel disease.

Authors:  E F Stange; W E Fleig; E Rehklau; H Ditschuneit
Journal:  Dig Dis Sci       Date:  1989-09       Impact factor: 3.199

10.  Preliminary report: cyclosporin in treatment of severe active ulcerative colitis.

Authors:  S Lichtiger; D H Present
Journal:  Lancet       Date:  1990-07-07       Impact factor: 79.321

View more
  4 in total

1.  Post-liver transplant Crohn's disease: graft tolerance but not self-tolerance?

Authors:  Alnoor Ramji; David A Owen; Siegfried R Erb; Charles H Scudamore; Eric M Yoshida
Journal:  Dig Dis Sci       Date:  2002-03       Impact factor: 3.199

2.  Crohn's ileitis after liver transplantation from a living related donor with Crohn's disease.

Authors:  K A Papadakis; R Matuk; M T Abreu; E A Vasiliauskas; P R Fleshner; J Lechago; T Tran; F F Poordad; P Martin; J Vierling; S R Targan
Journal:  Gut       Date:  2004-09       Impact factor: 23.059

3.  Ulcerative colitis after renal transplantation: A case report and review of literature.

Authors:  S Parameswaran; K Singh; R Nada; M Rathi; H Kohli; V Jha; K Gupta; V Sakhuja
Journal:  Indian J Nephrol       Date:  2011-04

4.  De novo ulcerative colitis after kidney transplantation treated with infliximab.

Authors:  Rikako Oki; Sumi Hidaka; Akiko Sasaki; Shinichi Teshima; Yasuhiro Mochida; Katsunori Miyake; Kunihiro Ishioka; Hidekazu Moriya; Takayasu Ohtake; Shuzo Kobayashi
Journal:  CEN Case Rep       Date:  2021-04-07
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.